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Abstract
Objectives. GCA is characterized by arterial remodelling driven by inflammation. IL-22 is an attractive
cytokine which acts at the crosstalk between immune and stromal cells. We hypothesized that IL-22 might
be induced in GCA and might be involved in disease pathogenesis.
Methods. Patients subjected to temporal artery biopsies (TABs) naı¨ve from therapy were enrolled: 27
biopsy-proven GCA, 8 biopsy-negative GCA, 21 biopsy-negative non-GCA patients. Expression of IL-22
was determined in TABs by immunohystochemistry, in plasma by ELISA, in peripheral blood mononuclear
cells by real-time PCR and flow cytometry. Effects of IL-22 on viability and gene expression of primary
cultures obtained from TABs were also evaluated.
Results. Inflamed TABs from GCA patients showed a higher expression of IL-22 and IL-22 specific
receptor subunit (IL-22R1) than non-inflamed TABs. IL-22 was expressed in infiltrating immune cells
and spindle shaped cells, IL-22R1 was expressed in endothelial cells. Patients with biopsy-proven GCA
showed increased levels of IL-22 in plasma than patients with biopsy-negative GCA, without GCA and
healthy subjects. Peripheral blood mononuclear cells from GCA patients expressed higher IL-22 transcript
than healthy subjects. After stimulation in vitro with phorbol 12-myristate 13-acetate and ionomycin, the
frequencies of Th22 and IL-22+ CD4+ lymphocytes were similar between patients with and without GCA.
Treatment with IL-22 of primary cultures obtained from TABs increased cell viability under stress condi-
tions and expression of B-cell activating factor.
Conclusion. IL-22 is increased in patients with GCA and affects viability and gene expression of arterial
cells, supporting a potential role in disease pathogenesis.
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Rheumatology key messages
. IL-22 and IL-22R1 are expressed at higher levels in inflamed temporal artery biopsies from GCA patients.
. Patients with biopsy-proven GCA have increased levels of IL-22 in plasma.
. IL-22 might contribute to arterial remodelling and B cell responses in patients with GCA.
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Introduction
Giant cell arteritis (GCA) is the most common vasculitis in
western countries in individuals older than 50 years of age.
It is a chronic inflammatory disease affecting large and
medium-sized arteries, especially the branches of the
proximal aorta [1, 2]. What triggers GCA is actually un-
known. What is known is that arteries from GCA patients
show granulomatous infiltrate mainly consisting of CD4+ T
lymphocytes of Th1 and Th17 subsets and macrophages
with an increased production of cytokines (e.g. IFNg,
TNFa, IL-1b, IL-2, IL-6, IL-9, IL-17 and IL-21), growth fac-
tors (e.g. vascular endothelial growth factor, fibroblast
growth factor-2, platelet-derived growth factor, endothe-
lin-1), elastolytic and proteolytic enzymes [1, 3, 4].
Inflammation leads to arterial remodelling and intimal
hyperplasia with possible subsequent stenoses or occlu-
sions resulting in ischaemic events [5].
IL-22 belongs to the IL-10 cytokine family. It signals
through a heterodimeric receptor composed of a chain
specific for IL-22 (IL-22R1) and a chain shared with
IL-10 (IL-10R2). What makes IL-22 attractive is that it is
produced by immune cells but acts only on non-haema-
topoietic cells because IL-22R1 has been detected only in
stromal cells (e.g. epithelial and endothelial cells and fibro-
blasts). IL-22 has been reported to regulate the crosstalk
between cells of the immune system and tissue-resident
cells, particularly at barrier surfaces (e.g. respiratory,
gastrointestinal systems and skin) [6, 7]. It has immuno-
modulator properties in infection, inflammation, auto-
immunity, cancer, tissue regeneration and host defence.
It is noteworthy that IL-22 increased expression can be
either pathological or protective, depending on the dur-
ation and amount of IL-22, the overall cytokine milieu and
tissue type [8]. We hypothesized that IL-22 might be ex-
pressed in GCA because IL-6, IL-21 and Notch pathways,
which are activated in GCA [913], can induce the pro-
duction of IL-22 [14]. Moreover, IL-22 might have a role in
arterial remodelling, because it regulates the intercommu-
nication between the immune system and stromal cells.
At the moment, no data are available on the IL-22 path-
way in GCA. Our aim was to investigate if IL-22 is differ-
entially expressed by patients with GCA compared with
patients without GCA and determine the effects of IL-22
on primary cultures obtained from arteries.
Methods
Patients
Temporal artery biopsies (TABs) were performed for diag-
nostic purposes to confirm GCA histologically [2, 15, 16].
Two cohorts of patients subjected to TABs for a suspicion
of GCA were included in the study. All patients were naı¨ve
for corticosteroid therapy at the time of TAB and blood
withdrawal. One cohort was enrolled at the section of
Rheumatology at the University of Palermo and was dedi-
cated to immunohistochemistry analyses on TABs. It
included 15 patients with GCA with inflamed TABs and
12 patients with non-inflamed TABs who received a
different diagnosis. All patients with GCA and none of
the non-GCA patients satisfied the ACR criteria for GCA
[17]. The other cohort was recruited at the section of
Rheumatology at the Arcispedale Santa Maria Nuova-
IRCCS (Reggio Emilia, Italy) from June 2012 to June
2016 and was dedicated to systemic analyses on
plasma and peripheral blood mononuclear cells
(PBMCs). It included the following: patients with GCA
with positive TABs showing transmural inflammation as
defined by Cavazza et al. [16] (n = 12); patients with nega-
tive, non-inflamed TABs diagnosed with GCA on the basis
of clinical, imaging, laboratory findings and follow-up
evaluation (n = 8; median age: 74 years, interquartile
range (IQR): 6781 years; median follow-up: 10 months,
IQR: 725 months); and patients with negative TABs who
received a different diagnosis (non-GCA patients; n = 9).
All patients with TAB-positive GCA, 7/8 patients with TAB-
negative GCA and none of the non-GCA patients satisfied
the ACR criteria for GCA. The two cohorts of patients were
similar regarding demographic and clinical features with
the exception of TAB-positive GCA patients from Reggio
Emilia who were older compared with TAB-positive GCA
patients from Palermo (supplementary Table S1, available
at Rheumatology Online).
For systemic analyses, 12 age-matched healthy sub-
jects were recruited as unaffected controls. Their
median age was 77 years (IQR: 7278 years). They did
not have any autoimmune diseases, cardiovascular dis-
eases, infections and cancers.
This study was approved by the Local Ethics
Committee (Reggio Emilia, Italy) in compliance with the
Declaration of Helsinki and informed consent was ob-
tained from all patients and healthy subjects.
Biologic samples
Peripheral blood was collected in EDTA-coated tubes.
PBMCs were isolated by histopaque-1077 density gradi-
ent centrifugation (Sigma-Aldrich, St Louis, MO, USA) and
stored frozen in liquid nitrogen in 90% heat-inactivated
fetal bovine serum (FBS, Gibco, Thermo Fisher
Scientific, Waltham, MA, USA) 10% dimethyl sulfoxide
(Sigma-Aldrich) until use.
Immunohistochemistry
TABs were immediately fixed with 4% formaldehyde and
embedded in paraffin. Immunohistochemical analysis for
IL-22, IL-22R1 and B cell activating factor (BAFF) was
performed on 5-mm-thick paraffin-embedded sections
from arteries and from tonsils (used as positive controls)
as previously described [18, 19]. Rabbit polyclonal anti-
human IL-22 (1:200 dilution) (Novus Biologicals, Littleton,
CO, USA), rabbit polyclonal anti-human IL-22R1 (1:100
dilution) (Novus Biologicals) and rabbit polyclonal anti-
human BAFF (1:200 dilution) (Abcam, Cambridge, UK)
were used as primary antibodies. The isotype-matched
irrelevant rabbit IgG polyclonal antibody (ab27472,
Abcam) was used as negative control. The number of
IL-22, IL-22R1 and BAFF expressing cells was determined
by counting immunoreactive cells on photomicrographs
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obtained from three randomly obtained high-power micro-
scopic fields under a DM2000 optical microscope, using a
DFC320 digital camera (Leica, Wetzlar, Germany).
ELISA
Concentration of IL-22 in plasma was determined with the
Human IL-22 ELISA kit from RayBiotech (Norcross, GA,
USA) following the manufacturer’s instructions. Plasma
was diluted 2-fold with assay diluent A as recommended
by the manufacturer. Standards and samples were incu-
bated overnight at 4 C with gentle shaking. The experi-
mental minimum detectable dose of IL-22 was 32 pg/ml.
The intra-assay coefficient of variation was <10% and the
inter-assay coefficient of variation was <12%.
IL-22 treatment of primary cultures from TABs
Primary cultures were obtained from TABs following the
method developed by Lozano et al. [20] and recently
described [19]. Such cultures showed a myofibroblast
phenotype expressing markers of smooth muscle cells
(smooth muscle a-actin) and fibroblasts (fibroblast activat-
ing protein and fibroblast specific protein) but not of
endothelial cells (von Willebrand factor), determined by
real-time PCR. Forty thousand cells were seeded in
each well of six-well plates in 2 ml DMEM with high glu-
cose + 10% FBS (Gibco, Thermo Fisher Scientific), 2 mM
glutamine and 50 mg/ml gentamicin (Sigma-Aldrich) and
cultured at 37 C, 5% CO2. After 24 h they were treated
with IL-22 (50 ng/ml) (research grade from Miltenyi Biotec,
Bergisch Gladbach, Germany) in 2 ml complete medium.
Cells were collected after 6 and 24 h of treatment for gene
expression analyses.
Cell viability
Cells obtained from TABs were seeded at 1500 cells per
well in 96-well plates in 100ml DMEM with high glu-
cose + 10% FBS, 2 mM glutamine and 50 mg/ml gentami-
cin. The following day medium was replaced with medium
containing IL-22 (10, 50, 100 ng/ml) in the presence and
absence of FBS. Treatment was renewed every 72 h. To
assess cell viability, the proliferation reagent WST-1
(Sigma-Aldrich) was used (1:10 final dilution) and optical
density at 450 and 620 nm was measured after 4 h incu-
bation at 37 C, 5% CO2.
Gene expression analysis
Total RNA was extracted from the primary cultures and
PBMCs with the miRNeasy micro kit (Qiagen, Hilden,
Germany). RNA (62.5 ng) was retro-transcribed with the
Takara (Kusatsu, Japan) reverse transcription kit in a
total volume of 20ml following the manufacturer’s instruc-
tion with the elimination of genomic DNA. cDNA was
diluted twice with RNase and DNase free water then ex-
pression of IL-22 (Hs01574154_m1), IL-22R1 (Hs00222
035_m1), BAFF (Hs00198106_m1), a proliferation-inducing
ligand (APRIL; Hs00601664_g1), chemokine (C-X-C motif)
ligand 13 (CXCL13; Hs00757930_m1) and chemokine (C-C
motif) ligand 21 (CCL21; Hs00989654_g1), was quantified
by real-time PCR with TaqMan gene expression assays
and master mix (all from Thermo Fisher Scientific).
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH;
Hs02758991_g1, Thermo Fisher Scientific) was used to
normalize data.
Flow cytometry
PBMCs were thawed and counted with a Fuchs-
Rosenthal haemocytometer (Sigma-Aldrich). After over-
night resting at 37 C, 5% CO2 in RPMI 1640 + 10% heat
inactivated FBS, PBMCs were stimulated for 4 h with
50 ng/ml phorbol 12-myristate 13-acetate (PMA) and
1mg/ml ionomycin (Sigma-Aldrich) at 1  106 cells in
1 ml RPMI 1640 + 10% FBS. After 30 min stimulus, brefel-
din A (Sigma-Aldrich) was added at 10 mg/ml. Cells were
collected and stained with 100ml Live/Dead Fixable Dead
Cell Stain near-IR-fluorescent reactive dye at 0.1% in PBS
(Thermo Fisher Scientific) for 10 min at room temperature
and then with antibodies against the surface antigens CD4
and CD56 for 20 min at room temperature. PerCP-Cy5.5
mouse anti-human CD4 (clone RPA-T4, from BD) and PE
anti-human CD56 (clone REA196 from Miltenyi Biotec)
were diluted in 100 ml PBS. After washing with PBS + 1%
FBS, PBMCs were fixed and permeabilized with 250 ml BD
Cytofix/Cytoperm Fixation/Permeabilization solution (BD
Biosciences, San Jose, CA, USA) for 20 min at 4 C.
After two washing with the BD Perm/Wash buffer,
PBMCs were stained with antibodies against intracellular
cytokines: anti-human IL-17A PE-Cyanine7, anti-human/
mouse IL-22 APC, anti-human IFN-g Alexa Fluor 488 (all
from Thermo Fisher Scientific) in 100ml Perm/Wash buffer
for 30 min at 4 C. Antibodies were diluted as recom-
mended by the manufacturers. After two washing with
the BD Perm/Wash buffer, PBMCs were resuspended in
PBS + 1% FBS and acquired with the FACSCanto II (BD
Biosciences). Data were analysed with FACSDiva soft-
ware (BD Biosciences). At least 60000 live lymphocytes
were acquired.
Statistical analysis
Statistical analyses were performed with Prism 6 software
(GraphPad Software, La Jolla, CA, USA). The Mann
Whitney U test was used for comparisons between two
groups, Spearman’s test was used for correlations be-
tween two variables and a receiver operating characteris-
tic curve was used to assess the performance of a binary
classifier system. Fisher’s exact test was used to analyse
tables. P < 0.05 (two-tailed) was considered statistically
significant.
Results
Increased expression of IL-22 and IL-22R1 in
inflamed TABs
To evaluate whether IL-22 and its specific receptor (IL-
22R1) were expressed in TABs and by which kinds of
cells, immunohistochemistry was performed on inflamed
TABs from GCA patients (n = 15) and normal TABs from
non-GCA patients (n = 12). IL-22 was detected in infiltrat-
ing immune cells and spindle-shaped cells in inflamed
www.rheumatology.oxfordjournals.org 3
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TABs (Fig. 1A), at a higher level in inflamed than normal
TABs (comparison between Fig. 1A and B). Expression of
IL-22R1 was detected in endothelial cells facing the arter-
ial lumen and some adventitial cells, more in inflamed than
normal TABs (comparison between Fig. 1C and D). The
number of immunoreactive cells per field was significantly
higher in inflamed compared with normal TABs for both
IL-22 and IL-22R1 (Fig. 1E and F).
Systemic production of IL-22
To investigate whether IL-22 was deregulated systemic-
ally, levels of IL-22 were determined in plasma and
PBMCs from patients with GCA (both TAB positive and
TAB negative), patients subjected to TABs but with a final
diagnosis different from GCA and a cohort of age
matched healthy subjects. Concentration of IL-22 in
plasma was significantly higher in patients with TAB posi-
tive GCA compared with patients with TAB negative GCA,
non-GCA patients and healthy controls (Fig. 2A). Patients
with TAB positive GCA clustered in two groups: with a
concentration of IL-22 higher than 277 pg/ml and with a
concentration of IL-22 equal to or lower than 277 pg/ml.
This cut-off level classified patients with TAB positive GCA
vs healthy subjects with 58% sensitivity and 92% specifi-
city and vs TAB negative non-GCA patients with 58% sen-
sitivity and 89% specificity by means of receiver operating
characteristic analysis (area = 0.8681, P = 0.002 and
area = 0.7824, P = 0.030, respectively). Patients with a
clinical diagnosis of GCA but with a negative TAB had
levels of IL-22 equal to non-GCA patients and healthy
subjects (Fig. 2A).
To determine whether circulating levels of IL-22 were
associated with demographic and clinical parameters, pa-
tients subjected to TAB were divided according to the cut-
off level of IL-22. There were no differences in the analysed
parameters at diagnosis between patients with higher and
lower IL-22 concentration in plasma (Table 1). Nevertheless,
there was a positive correlation between IL-22 and CRP
levels (Spearman’s test, P = 0.0310, r = 0.4012, n = 29).
We then analysed levels of IL-22 in PBMCs ex vivo (by
real-time PCR and flow cytometry) and after 4 h stimula-
tion with PMA and ionomycin in the presence of brefeldin
A (by flow cytometry). The known cellular sources of IL-22
are T helper cells (Th1, Th17, Th22), NK cells, CD8+ T
cells, gd T cells, innate lymphoid cells of group 3 and
fibroblasts [7, 14]. We analysed CD4+ T helper and
CD56+ NK lymphocytes by flow cytometry.
IL-22 transcript was higher in PBMCs from patients with
TAB positive GCA compared with healthy subjects but no
differences were found between patients with TAB posi-
tive GCA and those with TAB negative GCA and without
GCA (Fig. 2B). There was a positive correlation between
FIG. 1 Presence of IL-22 and IL-22R1 in temporal artery biopsies
(AD) Representative images showing the expression of IL-22 and IL-22R1 in inflamed (A, C) and non-inflamed
(B, D) TABs by immunohystochemistry. Diaminobenzidine was used as chromogen (Dako, Agilent, Santa Clara, CA, USA)
and slides were slightly counterstained with haematoxylin before dehydration and mounting in DePex (VWR International,
Milan, Italy). (E, F) Semi-quantitative analysis of IL-22 (E) and IL-22R1 (F) expressing cells in inflamed (n = 15) and non-
inflamed (n = 12) TABs. Whiskers represent the 5th and the 95th percentile. Data were compared by the MannWhitney
U test. IL-22R1: interleukin-22 receptor specific chain; TAB: temporal artery biopsy.
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FIG. 2 Systemic production of IL-22
(A) Concentration of IL-22 in plasma was determined by ELISA. Each symbol represents an individual subject. Horizontal
lines show the median. (B) Box plot visualization of the levels of IL-22 mRNA in PBMCs ex vivo determined by real-time
PCR. Expression as 2Ct (where Ct is IL-22 Ct  GAPDH Ct) is shown on the y-axis. The median Ct of IL-22 amp-
lification product in PBMCs from TAB positive GCA patients was 36.3; the median Ct of GAPDH was 24.4. (C) Box plot
visualization of the frequencies of IL-22+ and Th22 (IL-22+ IL-17 IFNg) cells in the CD4+ lymphocyte gate determined by
flow cytometry after 4 h stimulation of PBMCs in vitro with PMA + ionomycin in presence of brefeldin A. Dead cells were
excluded from analysis. Whiskers represent the 5th and the 95th percentile. Analyses were performed on plasma
samples and PBMCs from 12 biopsy-proven GCA patients (TAB pos GCA), 8 biopsy-negative GCA patients (TAB neg
GCA), 9 biopsy-negative non-GCA patients (TAB neg CTR) and 12 healthy subjects (Healthy CTR). Data were analysed by
MannWhitney U test. Ct: threshold cycle; GAPDH: glyceraldehyde 3-phosphate dehydrogenase; PBMC: peripheral
blood mononuclear cell; PMA: phorbol 12-myristate 13-acetate; TAB: temporal artery biopsy.
TABLE 1 Characteristics of patients stratified on the basis of circulating levels of IL-22
Demographic, clinical and laboratory characteristics
IL-22> 277pg/ml IL-224 277pg/ml
(n =9) (n = 20)
Age at disease onset, median (IQR), years 80 (7182) 74 (6778)
Any cranial symptomsa, n (%) 7 (78) 16 (80)
Abnormalities of temporal arteriesb, n (%) 6/7 (86) 8/19 (42)
Any visual symptoms, n (%) 2 (22) 2 (10)
Systemic signs/symtomsc, n (%) 6 (67) 13 (65)
PMR, n (%) 5 (56) 10 (50)
ESR, median (IQR), mm/h 82 (7095) 62 (1490)
CRP, median (IQR), mg/dl 3.6 (3.112.0) 3.2 (0.87.2)
Haemoglobin, median (IQR), g/dl 11.7 (10.513.6) 12.6 (11.413.0)
Platelets, median (IQR), 103/ml 352 (276406) 310 (233405)
Leucocytes, median (IQR), 103/ml 8.5 (6.810.0) 8.3 (7.410.0)
Lymphocytes, median (IQR), 103/ml 1.6 (1.52.1) 1.8 (1.42.2)
Monocytes, median (IQR), 103/ml 0.7 (0.50.8) 0.6 (0.40.7)
Neutrophils, median (IQR), 103/ml 6.1 (4.07.6) 6.0 (4.17.5)
aAt least one of the following: headache, scalp tenderness, jaw claudication. bTemporal artery tenderness to palpation or
decreased pulsation. This information was not available for all patients. cAt least one of the following: fatigue, anorexia, weight
loss of at least 4 kg, fever. IQR: interquartile range; TAB: temporal artery biopsy.
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concentration of IL-22 in plasma and levels of IL-22 tran-
script in PBMCs (Spearman’s test, P = 0.0415, r = 0.3809,
n = 29).
Production of IL-22 was not detected by flow cytometry
in unstimulated PBMCs but was detected after stimulation
with PMA and ionomycin. The percentages of IL-22+ and
Th22 cells in the CD4+ lymphocyte gate were similar in
patients with TAB positive GCA, TAB negative GCA, with-
out GCA and healthy controls (Fig. 2C). The Th22 subset
was defined as IL-22+ IFNg IL-17 CD4+ lymphocytes.
There were also CD4+ lymphocytes expressing both IL-22
and IL-17 or IL-22 and IFNg, with no differences between
groups (data not shown). More than 94% of the IL-22 ex-
pressing lymphocytes were CD4+. CD56+ lymphocytes
did not produce or negligibly produced IL-22.
IL-22 effects on primary cultures obtained from TABs
To determine possible effects of IL-22 on arterial cells,
primary cultures obtained from normal TABs were treated
in vitro with IL-22. Cells could be treated up to 96 h in the
absence of FBS; afterwards they started to detach. In the
presence of FBS, cells were treated for a longer time
(168 h) because they grow slowly with a duplication time
of about 168 h. Treatment with IL-22 in the absence of
FBS dose-dependently increased cell viability evaluated
by the WST-1 metabolic assay (Fig. 3A, left) while treat-
ment with IL-22 in the presence of 10% FBS did not affect
cell viability (Fig. 3A, right). It has been shown that IL-22
can favour production of chemokines and assembly of
tertiary lymphoid organs [21]. Treatment with IL-22 of pri-
mary cultures obtained from TABs increased gene ex-
pression of BAFF and IL-22R1 while it did not modify
APRIL, CXCL13 or CCL21 gene expression (Fig. 3B).
There was a change greater than 2-fold in BAFF gene
expression between IL-22 treated and untreated cells in
all the cultures after 6 h treatment and in 2/3 cultures after
24 h treatment. IL-22R1 gene expression was significantly
increased only after 6 h treatment with IL-22 (Fig. 3B).
Correlation between IL-22 and BAFF levels in TABs
To verify whether IL-22 was biologically active in TABs,
levels of BAFF were determined by
FIG. 3 Effects of IL-22 on primary cultures obtained from temporal artery biopsies
(A) Cultures obtained from TABs were treated with different doses of IL-22 in absence and presence of FBS. Cell viability
was determined through the WST-1 colorimetric assay. OD is shown relative to that of untreated cells. (B) Cultures
obtained from TABs were treated with 50 ng/ml IL-22 for 6 h and 24 h. Expression of CCL21, BAFF, APRIL, CXCL13, IL-
22R1 was determined by real-time PCR and is shown relative to that of untreated cells by the formula: 2Ct. Bars
represent the mean with SEM of three independent experiments performed on three different cultures. Data were
analysed by one sample t-test vs a theoretical mean of 100 (A) or 1 (B). APRIL: a proliferation-inducing ligand; BAFF,
B cell activating factor; CCL21: chemokine (C-C motif) ligand 21; CXCL13: chemokine (C-X-C motif) ligand 13; FBS: fetal
bovine serum; IL-22R1: interleukin-22 receptor specific chain; OD, optical density; TAB: temporal artery biopsy.
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immunohistochemistry. BAFF expression was observed in
neo-vessels and smooth muscle cells present in the
medial layer, in infiltrating inflammatory mononuclear
cells as well as in the context of granulomatous inflamma-
tion (Fig. 4A and B). The number of BAFF positive cells per
field was significantly higher in inflamed than normal TABs
(Fig. 4C) and directly correlated with the number of IL-22
positive cells per field in inflamed TABs (Fig. 4D).
Discussion
This is the first report about the IL-22 pathway in GCA. We
found that IL-22 and IL-22R1 were expressed in TABs at
higher levels in inflamed TABs from patients with GCA
compared with normal, non-inflamed TABs. In addition,
concentration of IL-22 was increased in plasma from
biopsy-proven GCA patients compared with healthy sub-
jects and biopsy-negative GCA and non-GCA patients.
We might speculate that temporal artery inflammation is
necessary but not sufficient to increase circulating levels
of IL-22 and that pathways upstream of the systemic pro-
duction of IL-22 are activated in a subset of biopsy-proven
GCA patients (see below) but not in biopsy-negative GCA
patients.
IL-22 transcript was detected in PBMCs from GCA pa-
tients ex vivo, but at a low level. Accordingly, IL-22 protein
was not detected in PBMCs unless they were stimulated
with PMA plus ionomycin in vitro, meaning that IL-22 pro-
duction mainly occurs at the tissue level where lympho-
cytes are activated. IL-22 expressing lymphocytes in
PBMCs were mainly CD4+ (including Th1 and Th17
lymphocytes) and the CD4 negative ones were not
CD56+, indicating that circulating cells of the NK lineage
did not produce IL-22 in GCA.
Two subsets of biopsy-proven GCA patients, who did
not differ clinically and demographically at diagnosis,
emerged on the basis of plasmatic concentration of IL-
22: high and low producers. This might reflect an
enhanced activation of pathways upstream of IL-22
production (e.g. IL-6, IL-21, IL-23, Notch and aryl hydro-
carbon receptor) [14] in a subset of patients. In particular,
IL-23 is the main factor driving IL-22 expression in vivo,
which seems indispensable for IL-22 induction during in-
flammation. Data on IL-23 in GCA are scarce but indicate
a likely activation of the IL-23 pathway. Indeed, PBMCs
from GCA patients showed a higher production of IL-23
than those from healthy subjects after stimulation with
PMA plus ionomycin [12, 22]. Moreover, IL-23p19 peptide,
one of the subunits of IL-23, has been recently detected in
inflamed TABs, likely inducing expression of adhesion
molecules in endothelial cells and favouring leucocyte at-
tachment and transendothelial migration [23].
FIG. 4 Correlation between IL-22 and B cell activating factor levels in inflamed temporal artery biopsies
(A, B) Representative images showing BAFF immunostaining in inflamed TABs from GCA patients. (C) Semi-quantitative
analysis of BAFF-positive cells in inflamed (n = 15) and non-inflamed (n = 12) TABs. Whiskers represent the 5th and the
95th percentile. Data were compared by the MannWhitney U test. (D) Correlation between the number of BAFF-positive
cells and IL-22-positive cells in inflamed TABs (Spearman’s correlation, n = 15). BAFF: B cell activating factor; TAB:
temporal artery biopsy.
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IL-22 and Th22 lymphocytes have been found deregu-
lated in other inflammatory and autoimmune diseases.
Therefore the IL-22IL-22R1 axis is emerging as an
attractive target for therapeutic interventions [24]. In par-
ticular, there is good evidence that inhibiting the IL-22IL-
22R1 axis could be beneficial in psoriasis, while its
enhancement could be beneficial in inflammatory bowel
diseases [24], which underlies that this axis is two-faced.
Increased production of IL-22 and/or frequency of Th22
have been reported also in patients with RA, spondyloar-
thritis, SLE, multiple sclerosis, Behc¸et’s disease, myositis
and SS, but their role in these disease is still controversial
and needs further investigations [18, 2527].
IL-22 and Th22 lymphocytes have also been found
deregulated in cardiovascular diseases, which can have
some pathogenic overlaps with GCA. Levels of IL-22 in
plasma and Th22 lymphocytes are increased in patients
with acute myocardial infarction and unstable angina
compared with stable angina and healthy controls [28].
Moreover, in a mouse model of atherosclerosis, IL-22 pro-
moted plaque formation and vascular repair by stimulating
dedifferentiation of medial smooth muscle cells into a syn-
thetic phenotype and migration into the intimal layer. Mice
deficient for IL-22 showed reduced plaque size compared
with mice expressing IL-22 [29]. These data suggest a
pathogenic role for IL-22 in cardiovascular diseases that
might also occur in GCA.
Our study has some limitations but also some strong
points. The number of patients was low and therefore it
is necessary to confirm our findings on larger cohorts.
However, we analysed only patients naı¨ve from therapy.
Having patients naı¨ve from therapy is difficult because as
soon as GCA is suspected, corticosteroid therapy must
be started to prevent ischaemic cranial events. Because
of this, only 29 patients with a suspicion of GCA reached
our hospital naı¨ve from therapy from June 2012 to June
2016. Another limitation of the present study is that al-
though we detected IL-22 as expressed at different
levels in GCA compared with non-GCA patients, the role
of IL-22 (pathogenic or protective) in GCA needs to be
further defined. However, in an attempt to identify pos-
sible effects of IL-22, we treated primary cultures obtained
from TABs with IL-22 in vitro. IL-22 increased cell viability
but only in the presence of stressed conditions (growth in
absence of FBS). Moreover, primary cultures from TABs
showed an increased expression of BAFF after treatment
with IL-22. There was a positive correlation between the
number of IL-22 and BAFF immunoreactive cells per field
in inflamed TABs indicating that IL-22 can signal in TABs.
BAFF regulates the proliferation, differentiation and main-
tenance of B cells. It has been shown to be increased in
TABs (data here and reference [19]) as well as in plasma
from GCA and PMR patients and associated with disease
activity [30]. We can thus speculate that IL-22 might be
involved in arterial remodelling and B cell responses in
patients with GCA.
In conclusion, we documented for the first time an
increased expression of IL-22 in temporal arteries and
plasma from patients with GCA and effects of IL-22 on
viability and gene expression of primary cultures estab-
lished from TABs, suggesting that IL-22 might be involved
in disease pathogenesis and unveiling a new potential
therapeutic target in GCA.
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